{"id":"W2902725138","doi":"10.1016/j.euo.2018.11.005","title":"Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Biotech; Janssen Research and Development; Genentech; European Society for Medical Oncology; Astellas Pharma; Eisai; Bayer; Canada Millennium Scholarship Foundation; Phycological Society of America; Amgen; Boehringer Ingelheim; Gilead Sciences; AbbVie; Sanofi; Novartis; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Clinical trial; Randomized controlled trial; Prostate-specific antigen; Cabazitaxel; Prostate; Cancer; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007184417,0.0003782874,0.002473142,0.0003963435,0.00007039379,0.00002014621,0.0001781598,0.0001845186,0.00007806328],"category_scores_gemma":[0.001356248,0.00021102,0.0001563939,0.0006355903,0.001593667,0.0001018743,0.00006964758,0.000772227,0.00002440483],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003607759,"about_ca_system_score_gemma":0.001528665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003845434,"about_ca_topic_score_gemma":0.005813152,"domain_scores_codex":[0.9896964,0.006214053,0.002096347,0.0008130232,0.000470446,0.00070975],"domain_scores_gemma":[0.9940342,0.003719901,0.001107838,0.0003671072,0.0005641895,0.0002068226],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4846984,0.001533315,0.5091861,0.00002034876,0.0007176731,0.00154377,0.0004624499,0.00001875737,0.000058013,0.00001034319,0.00007982834,0.001670991],"study_design_scores_gemma":[0.4597862,0.02553502,0.513005,0.00007577308,0.0004412797,0.00002892322,0.000112063,0.0001159401,0.00003268173,0.00001571793,0.0007047133,0.0001467679],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880523,0.0003013901,0.00003199818,0.003027281,0.0001195963,0.006308153,0.00003924749,0.00004995081,0.00207005],"genre_scores_gemma":[0.995367,0.0009430383,0.001618739,0.0003175211,0.0001973961,0.0004841521,0.0001041369,0.00007535412,0.0008926579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02491225,"threshold_uncertainty_score":0.8605146,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06802942518975472,"score_gpt":0.408579779599711,"score_spread":0.3405503544099563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}